ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2023

Abstract Number: 0171

A Conceptual Framework to Characterize the Indirect Burden of Systemic Lupus Erythematosus (SLE): Findings from Qualitative Patient Interviews

Vibeke Strand1, Prajakta Masurkar2, Jennifer Reckleff3, Taylor Schwartz4, Alison Silverstein4, Jennifer Osborne4, Josie Lloyd4, Brian Leinwand4, Elaine Karis5, Fatima Barbar-Smiley6 and Karen Costenbader7, 1Stanford University, Portola Valley, CA, 2Amgen, Inc., Atlanta, GA, 3Amgen, Inc., Westlake Village, CA, 4Inovalon Insights, Bowie, MD, 5Amgen, Inc., Colts Neck, NJ, 6Amgen, Inc., Dublin, OH, 7Brigham and Women's Hospital and Harvard Medical School, Boston, MA

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2023

Keywords: Health Services Research, Patient reported outcomes, Pharmacoepidemiology, quality of life, Systemic lupus erythematosus (SLE)

Session Information

Date: Sunday, November 12, 2023

Title: (0155–0175) Health Services Research Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: SLE is a chronic autoimmune disorder that affects multiple organs and leads to a variety of symptoms, including joint pain, fatigue, and skin rashes, that significantly impact patients’ lives. Despite the known increased risk of morbidity and mortality in affected populations, there has been limited research about the impact of SLE on a patient’s daily life, such as career achievements, social/leisure activities, and family dynamics. A qualitative study was conducted to examine the impact of SLE on daily life from a patient’s perspective and to develop a conceptual framework for overall impact.

Methods: A literature review was conducted to identify domains of interest to discuss in the interviews. A semi-structured interview guide was developed to gather patients’ perspectives on previously identified areas of SLE impact and identify other ways in which SLE affects daily life. Twenty adult patients with SLE consented to teleconference interviews to discuss how SLE impacted their lives. Transcripts were then analyzed to identify themes. Based on literature review and patient interviews, a preliminary conceptual framework was developed for understanding the indirect burden of SLE on patients.

Results: The literature review identified 10 domains of interest which were used as the topics of the in-depth interviews: career/education, social impact, physical activity, cost (direct/indirect), patient burden, family planning, treatment preference, clinical perspective, family burden, and mental health. Of the patients interviewed, a majority were female (95%), aged 30-39 years (40%), African American/Black (45%), and had employer-based insurance (70%) (Table 1). Over half of the patients reported ≥1 flare in the previous 12 months. Content analysis of interview transcripts revealed 8 domains based on patients’ perceptions of how SLE impacts their daily lives (percentage of patients reporting): physical activity/mobility (20%), reduced flares (15%), ability to work (10%), relationships/social life (45%), mental health (20%), fatigue (15%), inflammation/pain (20%), and direct/indirect healthcare costs (15%) (Table 2). Patients reported that the overall burden of SLE persisted despite treatment and increased with flares. The conceptual framework illustrates domains identified from the literature review and patient interviews (Figure 1). Previously studied domains included productivity, daily life, caregiver burden, and mental health. However, education, family/social lives, future planning, and other indirect costs were newly identified as domains that have not been well characterized.

Conclusion: Based on the literature review and in-depth patient interviews, a conceptual framework was developed for understanding the numerous factors contributing to the impact of SLE on patients’ lives in 8 discrete yet interrelated domains. Data reflecting the patient-centered burden of SLE in the literature are limited, especially with respect to the impact on education, family/social lives, future planning, and indirect costs. Future research should target these evidentiary gaps to better establish a holistic view of patient-centered SLE burden.

Supporting image 1

Table 1. Demographic and disease characteristics of SLE patients who were interviewed via teleconference

Supporting image 2

Table 2. Themes that emerged from in-depth patient interviews (N = 20)

Supporting image 3

Figure 1. A Conceptual Framework for Understanding the Indirect Patient Burden of SLE


Disclosures: V. Strand: Abbvie, 2, Alpine Immune Sciences, 2, Amgen, 2, Arena, 2, AstraZeneca, 2, Bayer, 2, Biosplice, 2, Bioventus, 2, Blackrock, 2, 2, BMS, 2, Boehringer Ingelheim, 2, Celltrion, 2, Chemocentryx, 2, EMD Serono, 2, Equillium, 2, Ermium, 2, Eupraxia Pharmaceuticals, 2, Flexion, 2, Galapagos, 2, Genentech/Roche, 2, Gilead, 2, GlaxoSmithKline, 2, Horizon, 2, Ichnos, 2, Inmedix, 2, Janssen, 2, Kiniksa, 2, 2, Kypha, 2, Lilly, 2, Merck, 2, MiMedx, 2, Novartis, 2, Omeros, 2, Pfizer, 2, Regeneron, 2, Rheos, 2, R-Pharm, 2, Samsung, 2, Sandoz, 2, Sanofi, 2, Scipher, 2, Setpoint, 2, Sorrento, 2, Spherix, 2, Tonix, 2, UCB, 2, Urica, 2; P. Masurkar: Amgen, 3; J. Reckleff: Amgen, 3; T. Schwartz: Amgen, 2, Life Sciences Companies, 2; A. Silverstein: Inovalon Insights, 3; J. Osborne: None; J. Lloyd: None; B. Leinwand: None; E. Karis: Amgen, Inc, 3, 11; F. Barbar-Smiley: Amgen, 3; K. Costenbader: Amgen, 2, 5, AstraZeneca, 5, Bristol-Myers Squibb(BMS), 2, Cabaletta, 2, Eli Lilly, 2, Exagen Diagnostics, 5, Gilead, 5, GlaxoSmithKlein(GSK), 2, 5, Janssen, 2, 5.

To cite this abstract in AMA style:

Strand V, Masurkar P, Reckleff J, Schwartz T, Silverstein A, Osborne J, Lloyd J, Leinwand B, Karis E, Barbar-Smiley F, Costenbader K. A Conceptual Framework to Characterize the Indirect Burden of Systemic Lupus Erythematosus (SLE): Findings from Qualitative Patient Interviews [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/a-conceptual-framework-to-characterize-the-indirect-burden-of-systemic-lupus-erythematosus-sle-findings-from-qualitative-patient-interviews/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-conceptual-framework-to-characterize-the-indirect-burden-of-systemic-lupus-erythematosus-sle-findings-from-qualitative-patient-interviews/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology